| Date | Article |
|---|---|
| Nov 7, 2011 | ApprovalFDA Approves Erbitux to Treat Late-stage Head and Neck Cancer |
| Dec 8, 2008 | Erbitux Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration |
Likewise, is Erbitux FDA approved?
FDA approves Erbitux (cetuximab) to treat patients with advanced colorectal cancer that has spread to other parts of the body.
Beside above, who developed Erbitux? "Bristol-Myers Squibb is incredibly proud to have built Erbitux into a major brand and an important therapy for so many patients with certain colorectal and head and neck cancers," said Murdo Gordon , head of worldwide markets, Bristol-Myers Squibb .
Beside above, when was Erbitux head and neck cancer diagnosed?
On November 7, the FDA approved cetuximab (Erbitux) in combination with platinum-based therapy plus fluorouracil (5-FU) for the first-line treatment of patients with recurrent locoregional disease and/or metastatic squamous cell carcinoma of the head and neck.
Is cetuximab an antagonist?
General information. Class/mechanism: EGFR antagonist; monoclonal antibody that binds to the EGFR/HER1/c-ErbB-1 receptor tyrosine kinase, competitively inhibiting binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
